Competing interests
Pierre, TTD, R.G-C., Neuroendocrine Tumour
ONCOLOGY
J.C. has participated as a scientific consultant for Amgen, Bayer, Eisai, AAA, Ipsen, Pfizer, Merck, Sanofi, Novartis, Lilly, ITM, Hutchinson Pharma and Exelixis; has received grants for research purposes from Eisai, AstraZeneca, AAA, Ipsen, Pfizer and Novartis; and is currently chair of the GETNE group, and advisory member of the European Neuroendocrine Tumour Society (ENETS) society. J.H. has participated as a speaker on behalf of Eisai, Ipsen, Novartis, AAA and Angelini. A.T. has participated as a speaker, advisor and received travel grants from Novartis, Ipsen, AAA, Pfizer and AstraZeneca. R.G-C. has participated as a scientific consultant for AAA, Advanz Pharma, Bayer, BMS, HMP, Ipsen, Merck, Midatech Pharma, MSD, Novartis, PharmaMar, Pfizer, Pierre Fabre, Roche, Sanofi and Servier; has received grants for research purposes from Pfizer, BMS and MSD; received institutional financial support from ARMO Biosciences, Astrazeneca, Pfizer, Novartis, Ipsen, Roche, Pharmacyclics, Boston Biomedicals, Merck, MSD, Amgen, Sanofi, Bayer, Bristol-Myers-Squibb, Boerhringer, Sysmex, Gilead Sciences, Servier, Adacap, VCN, Lilly and Pharmamar; and is currently a member of the Executive Committee of GETNE and ENETS, and member of the EORTC, ASCO, ESMO, SEOM, TTD, GEMCAD working groups. T.A.-G. has participated as a speaker on behalf of Ipsen, Pfizer, Adacap, BMS and Eisai; has participated as a scientific consultant for Ipsen, Pfizer, BMS, Eisai, Roche, Sanofi, Bayer, Astellas, Janssen-Cilag, Adacap and Lilly; has received grants for research purposes from Ipsen, Pfizer and Roche; has participated as scientific advisor at the Spanish Society of Medical Oncology (SEOM). G.C. has participated as a scientific consultant or speaker for BMS, MSD, Ipsen, Roche, Eisai, Sanofi, Janssen, Eusa Pharma and Pierre Fabre. I.S. has participated as a scientific consultant for Ipsen, Pfizer, AAA, Syrtex, Avanz Pharma, Pharmamar and Amgen; has participated as a speaker on behalf of Ipsen, Pfizer, Pierre Fabre, Pharmamar, Bayer and AAA. C.L. has participated as a scientific consultant for Ipsen, Roche, Eisai, Novartis, Pfizer, AstraZeneca, Pierre Fabre, Sanofi, Bayer, Servier and AAA; has received grants for research purposes from Ipsen, Roche, Pfizer, AstraZeneca, Pierre Fabre and Novartis. M.B. has participated as a speaker on behalf of Pfizer, Ipsen and Novartis. P.N. has participated as a scientific consultant for Bayer; and as a scientific consultant and speaker on behalf of MSD and Novartis. M.L. has participated as a scientific consultant for IPSEN, INCYTE, AAA; and as a speaker on behalf of AMGEN, SERVIER, IPSEN, PIERRE FABRE, AND AAA. V.A. has participated as a speaker on behalf of Ipsen, Amgen, Merck, Servier, AAA and Pierre Fabre; has participated as a scientific consultant for Ipsen, Roche, Sanofi and Merck. A.G.-A. has participated as a speaker on behalf of Angelini Pharma Spain; and received travel accommodation expenses from Pfizer, Ipsen and Eisai Europe. A.V. is employed by ICON plc. The remaining authors declare no competing interests.